Next Generation Cancer Diagnostics: Technologies and Global Markets

Report Highlights

BCC Research estimates the global market for next generation cancer diagnostic as $1.6 billion in 2013. This indication is expected to reach $1.8 billion in 2014 and $10 billion in 2019, registering a compound annual growth (CAGR) of 42.6% over the next five years.

Report Includes

• An overview of the global market for next generation cancer diagnostics and related technologies.
• Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
• Analyses of the diagnostics market by cancer indication (e.g., breast, colorectal, prostate, etc.), by type of analysis (e.g., gene expression, genotyping, proteomic, etc.), and by diagnostic function (e.g., screening/early detection, prognosis, monitoring/recurrence, and companion diagnostic).
• Examination of each technology format to determine its market status, impact on future market segments, and projected growth through the forecast period.
• Discussion on factors influencing the market including cancer diagnostics needs, regulatory trends, industry structure, and patent statuses.
• Assessments of the major next generation formats that are likely to become commercialized within the next five years.
• Profiles of companies in the industry as well as a look at corporate alliances.

Report Scope

The study scope includes the major next generation formats that are likely to become commercialized within the next five years. Each technology format is analyzed to determine its market status, impact on future market segments and projected growth from 2014 through 2019. Technology issues and forces driving the market are discussed. 

Influencing factors, including cancer diagnostic needs, regulatory trends, industry structure and patent status are also discussed.

BCC Research examines companies in the industry, corporate alliances and assay consumption by indication. More than 130 companies participating in the industry are profiled in this report.

Analyst Credentials

John Bergin has produced successful and highly regarded market research reports in the life science industry for BCC research for more than 10 years. Mr. Bergin has held business development and international sales and marketing positions with Corning Inc., an advanced materials company. He has also held executive management positions with IBC Advanced Technologies, a molecular recognition company specializing in separations. Mr. Bergin's extensive expertise in commercializing new technologies is reflected in his market research reports.

Mr. Bergin received a BS degree in Chemistry and Masters of Business Administration (MBA) degree from Brigham Young University and an MS degree in biotechnology from Johns Hopkins University. John Bergin is a pseudonym of the author.